Epigral Limited announced its financial results for the quarter ended September 30, 2026 (Q2 FY27), reporting a 26% year-over-year increase in Profit After Tax (PAT) to ₹64 crore. Revenue also saw a substantial jump of 28%, reaching ₹752 crore. This growth was attributed to volume increases and improved market realisations, with the Derivatives & Specialty business contributing 57% of revenue.
Epigral Limited Announces Strong Q2 FY27 Financials
Epigral Limited, a prominent integrated chemical manufacturer, has revealed robust financial performance for the second quarter of FY27, ending September 30, 2026. The company posted a notable 26% increase in Profit After Tax (PAT) compared to the same quarter last fiscal, reaching ₹64 crore from ₹51 crore in Q2 FY26. Quarterly revenue surged by 28% to ₹752 crore, up from ₹589 crore in the prior year’s corresponding period.
Key Performance Highlights for Q2 FY27
The company’s performance was underpinned by several key factors:
- Sales Volume Growth: YoY sales volume increased by 6% despite challenging market conditions.
- Revenue Growth Drivers: Revenue grew by 28% due to volume growth and significantly improved realisations.
- Business Segment Contribution: The Derivatives & Specialty business accounted for 57% of total revenue, an increase from 50% in Q2 FY26.
- EBITDA Performance: EBITDA stood at ₹136 crore compared to ₹132 crore in Q2 FY26. EBITDA margin was 18%, impacted by high raw material costs.
- PAT Growth: PAT saw a healthy increase of 26%, reaching ₹64 crore from ₹51 crore.
H1 FY27 Performance Remains Resilient
For the first half of FY27 (H1 FY27), Epigral Limited reported resilient performance:
- H1 Revenue: Revenue rose by 21% to ₹1,461 crore, compared to ₹1,204 crore in H1 FY26, navigating geopolitical tensions and volatile price movements.
- H1 EBITDA: EBITDA was ₹315 crore versus ₹296 crore, with the EBITDA margin maintained at 22%.
- H1 PAT: PAT increased by 25% to ₹164 crore from ₹131 crore in the previous year.
Strategic Outlook and Expansion Plans
Maulik Patel, Chairman and Managing Director, expressed optimism for the second half of the fiscal year. Despite a challenging operating environment, the company achieved strong revenue growth driven by volume and realisations. He highlighted that the CPVC and ECH expansions are nearing completion, with both plants expected to commission within a quarter. Progress is also on track for Epoxy Resin & Formulation and MPP projects. The company remains focused on enhancing its manufacturing ecosystem and expanding its portfolio of high-value chemical products.
Epigral has invested ₹88 crore in capex during H1 FY27. The board has also approved capex for two projects expected to commission by H2 FY28, including an Epoxy Resin & Formulations plant with a capacity of 1,25,000 TPA and a Multi-Purpose Plant (MPP) for the Epichlorohydrin (ECH) and Chlorotoluene Value Chain.
Source: BSE
